3 Shares For Your 2015 ISA: Lloyds Banking Group PLC, AstraZeneca plc And Barratt Developments Plc

Lloyds Banking Group PLC (LON: LLOY), AstraZeneca plc (LON: AZN) and Barratt Developments Plc (LON: BDEV) could get your 2015 ISA off to a great start.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

April brings our new 2015 ISA allowances, with a modest rise from last year’s £15,000 to £15,240. At the moment, the very best cash ISAs around would earn you about £240 in interest, and you should easily be able to beat that with shares. Here are three for you to consider:

Lloyds

Lloyds Banking Group (LSE: LLOY)(NYSE: LYG.US) recently announced its return to paying dividends — a yield of less than 1% for 2014, but the occasion was momentous nonetheless. Forecasts suggest a decent yield of 3.6% for this year, followed by 5.2% in 2016, and that’s serious cash again.

In fact, a yield of 5.2% extended to your entire ISA allowance would provide £792 in dividend cash alone — more than three times the interest on a cash ISA.

With profits back and liquidity ratios strengthening, Lloyds shares are on a forward P/E of only 10, dropping a little for 2016. That’s significantly cheaper than bailed-out rival Royal Bank of Scotland, which is at least a year behind in resuming dividend payments. Lloyds looks like a bargain to me.

AstraZeneca

If you want to see a terrific turnaround, look no further than what CEO Pascal Soriot has achieved at AstraZeneca (LSE: AZN)(NYSE: AZN.US). The FTSE 100 pharmaceutical company was struggling with loss of patent protection, a weak development pipeline, and plunging profits just a few short years ago.

Yet by refocusing on the company’s key strengths, offloading non-core businesses, and reinvesting in research and development, Mr Soriot has returned AstraZeneca’s pipeline to one of the best in the business, and we’re expecting a return to earnings growth by 2017 at the latest.

And while we’re waiting for that, there’s a 4.1% dividend yield on the cards, and it should be covered well enough to be safe.

Barratt

Does it make sense to buy a housebuilder that’s already climbed 17% in the past year and has more than quadrupled over five years? It’s Barratt Developments (LSE: BDEV), and I reckon it does.

For the year to June 2015, the City is expecting another 38% EPS rise from Barratt, followed by 18% in 2016. That’s slower than the meteoric earnings growth of recent years, but it would still leave the shares on a 2016 P/E of only around 10 — that really does show just how undervalued the housebuilding sector was at the depths of the recession.

Longer term growth seems pretty much assured too, as the UK’s housing shortage continues to bite and political parties are vying to make the best promises of boosting building. There were no dividends during the slump, but Barratt is on for a 4.4% yield this year followed by 5.4% next, and that looks very attractive to me.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »